8-K - NeuroOne Medical Technologies Corporation | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NeuroOne Medical Technologies Corporation stockholders approved amendments to its 2025 Equity Incentive Plan increasing the share reserve by 1,500,000 shares and adding annual evergreen increases, elected two Class III directors, ratified the auditor, and approved a reverse stock split at the April 3, 2026 Annual Meeting.

Key Takeaways

1Stockholders approved First Amendment to 2025 Equity Incentive Plan, increasing share reserve by 1,500,000 new shares.

2Plan now includes automatic annual increases of 5% of Fully Diluted Shares from Jan 1, 2027 to 2031, subject to Board discretion.

3Jeffrey Mathiesen and Edward Andrle elected as Class III directors for three-year terms ending 2029.

4Baker Tilly US, LLP ratified as independent auditor for fiscal year ending September 30, 2026.

5Amendment to Certificate of Incorporation approved for reverse stock split at 1-for-2 to 1-for-15 ratio, at Board discretion.

659.72% of outstanding shares present at Annual Meeting with 30,272,834 shares voted.

Current Report Details

Event Type

Management Change

Shareholder Vote

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** On Februa

Management Change

5.07

. Submission of Matters to a Vote of Security Holders.** At the annual meeting (the “Annual Meeting”) of stockholders of the Company on April 3, 2026, stockhold

Shareholder Vote

9.01

Financial Statements and Exhibits.** ** ** **(d) Exhibits** ** ** | Exhibit No. | | Description | |---|---|---| | 10.1 | | First Amendment to NeuroOne Medical T

Exhibits Only

Exhibits (2)

10.1

FIRST AMENDMENT TO NEUROONE MEDICAL TECHNOLOGIES CORPORATION 2025 EQUITY INCENTIVE PLAN

8-K

CURRENT REPORT